|PO Box 208042
New Haven, CT 06520-8042
Admin Assistant, Lori Raccio
The Yale-New Haven Hospital Nuclear Medicine Clinical Service, located in the new Smilow Cancer Hospital, provides many essential nuclear medicine studies for evaluation of infections, bone metastases, fractures, acute and chronic cholecystitis, scans for hyperparathyroid adenoma, congenital hypothyroidism, hyperthyroidism, cold nodules, extent of thyroid carcinoma involvement, and neuroendocrine tumor detection.
New additions include DaTscan (Ioflupane) scan for evaluation and differentiation of essential tremor from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy), Amyvid scans for suspected Alzheimer patients, Ra-223 therapy for bone pain palliation introduced in July 2013 as the first center to give this treatment in the state of Connecticut. We also provide studies for evaluation of differential renal function, renovascular disease, and UPJ obstruction, portal hypertension, gastrointestinal bleed localization, lung scan for differential lung function and pulmonary embolism, as well as tumor staging. and seizure focus localization using PET/CT scan. In terms of therapeutic treatments, we provide radioimmunotherapies, bone pain palliation, as well as radioiodine treatments for thyroid carcinoma patients.
There are 3 major services that place YNHH apart from most other hospitals in Connecticut. We have 2 PET/CT scanners with LySO crystal, one of which is equipped with state-of-the-art 64-slice CT, time of flight and respiratory gating. We have the highest volume of PET/CT studies and radioiodine treatments in the state. We get referrals from all over the state of CT, as well as from MA, NY and NJ. With a close working relationship with Dr. Udelsman, the chairman of Yale Department of Surgery, we have one of the highest sensitivity in parathyroid imaging in the country. We intend to keep improving the quality of our services to help our colleagues with theirs. Since 2008, we have established a Nuclear Medicine Consultation Clinic where we dedicate time to assess and to discuss radiation safety precautions with each patient.
The research mission of the Nuclear Medicine Division is realized through the formation of the Yale University Positron Emission Tomography Center (PET Center). The PET Center is being used to advance the interests of Yale clinicians, scientists and students in molecular imaging. The only focus of the PET Center is to conduct scientific research in human subjects and experimental animals. A new Siemens whole body PET/CT scanner with 128 slices CT has been added to the PET center for oncology and other research projects. There is a high-resolution brain PET scanner (Siemens HRRT), a whole body PET scanner, and a micro PET scanner in operation.
It is anticipated that the PET Center will develop interdepartmental scientific collaborations within the School of Medicine but also creates ties to basic science departments in the wider Yale University community in order to advance basic scientific research and participate in the education of doctoral and postdoctoral trainees.
- Molecular imaging and therapy
- PET and MR imaging
- Improving PET/CT imaging acquisition and quantification
- Validation of new clinical radiotracer
- Radiation exposure assessment
- Internal dosimetry
- Radioiodine treatment for thyroid disease
- Molecular imaging in neuroscience and neurotoxicology
- Small animal imaging, receptor binding assay and autoradiography
- Imaging Biomarkers
- Radioproteomics and Radiogenomics
- Clinical applications of positron imaging and single photon imaging in oncology and non-oncology areas
- Radio-targeted therapy
- Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S. Eur J Nucl Med Mol Imaging. 2019 Oct; 2019 Jul 30. PMID: 31363804.
- Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors.Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. PET Clin. 2019 Oct; 2019 Aug 7. PMID: 31472741.
- Neuroimaging in Dementias.Mahalingam S, Chen MK. Semin Neurol. 2019 Apr; 2019 Mar 29. PMID: 30925612.
- Kinetic evaluation and test-retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans.Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE. J Cereb Blood Flow Metab. 2018 Nov; 2017 Aug 9. PMID: 28792356.
- Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.Chen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. JAMA Neurol. 2018 Oct 1. PMID: 30014145.
- Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose.Ye Q, Wu J, Lu Y, Naganawa M, Gallezot JD, Ma T, Liu Y, Tanoue L, Detterbeck F, Blasberg J, Chen MK, Casey M, Carson RE, Liu C. Phys Med Biol. 2018 Sep 6; 2018 Sep 6. PMID: 30095083.
- Molecular imaging of prostate cancer.Boustani AM, Pucar D, Saperstein L. Br J Radiol. 2018 Apr; 2018 Feb 1. PMID: 29243485.
- Superior Pituitary Border Analysis in Immunotherapy-Induced Hypophysitis.Pucar D, Boustani AM, Bronen RA, Saperstein L. Clin Nucl Med. 2018 Apr. PMID: 29401149.
- Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis.Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H. Eur J Nucl Med Mol Imaging. 2017 Mar. PMID: 27987029.
- The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H. Eur J Nucl Med Mol Imaging. 2017 Mar; 2016 Dec 6. PMID: 27924371.
- Imaging synaptic density in the living human brain.Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE. Sci Transl Med. 2016 Jul 20. PMID: 27440727.
- Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Br J Cancer. 2016 Mar 29. PMID: 27022826.
- Determining the Minimal Required Radioactivity of 18F-FDG for Reliable Semiquantification in PET/CT Imaging: A Phantom Study.Chen MK, Menard DH 3rd, Cheng DW. J Nucl Med Technol. 2016 Mar; 2016 Jan 14. PMID: 26769598.
- (11)C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas.Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF, O'Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N, Leppert D, Huang Y, Carson RE, Pelletier D. Eur J Nucl Med Mol Imaging. 2015 Jun; 2015 Apr 2. PMID: 25833352.
- Further evaluation of [11C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis.Lin SF, Labaree D, Chen MK, Holden D, Gallezot JD, Kapinos M, Teng JK, Najafzadeh S, Plisson C, Rabiner EA, Gunn RN, Carson RE, Huang Y. Synapse. 2015 Feb; 2014 Dec 11. PMID: 25450608.
- What is the role of dosimetry in patients with advanced thyroid cancer?Chen MK, Cheng DW. Curr Opin Oncol. 2015 Jan. PMID: 25319079.
- Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta).Caporizzo DJ, Kwiatkowski AE, Chen MK, Beck AP, Booth CJ, Zeiss C, Smith PC, Carlson Scholz JA, Wilson SR. Comp Med. 2014 Jun. PMID: 24956213.
- ¹¹¹In-DTPA cisternography with SPECT/CT for the evaluation of normal pressure hydrocephalus.Thut DP, Kreychman A, Obando JA. J Nucl Med Technol. 2014 Mar; 2014 Jan 24. PMID: 24463341.
- The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer.Chen MK, Yasrebi M, Samii J, Staib LH, Doddamane I, Cheng DW. Thyroid. 2012 Mar; 2012 Feb 2. PMID: 22300251.
- Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management.Chen MK, Doddamane I, Cheng DW. Curr Opin Oncol. 2010 Jan. PMID: 19844179.
- Primary non-Hodgkin's lymphoma of the liver.Noronha V, Shafi NQ, Obando JA, Kummar S. Crit Rev Oncol Hematol. 2005 Mar. PMID: 15718146.